At present, the domestic market by foreign pharmaceutical companies accounted for 75% of the share, and the most exclusive high-end ophthalmic products by foreign-invested enterprises, domestic pharmaceutical companies to enhance scientific and technological content of products imminent.
In April 2008, Novartis spent 11 billion U.S. dollars of professional ophthalmic pharmaceutical company acquired 25% stake in Alcon, and said the future will be invested 28 billion U.S. dollars to buy the remaining shares. In the context of economic crisis, Novartis has invested nearly 40 billion yuan acquisition of a billion dollars in annual sales of only 60 companies, many of whom are baffled. After all, Pfizer buy Wyeth over the same period (2008 annual sales of 29 billion U.S. dollars) is also just 600 billion dollars. However, the completion of the acquisition, Novartis chairman and chief executive Daniel Vasella has claimed that this acquisition is very cost-effective, because with the advent of an aging society, ophthalmic drug market will be a hot profit growth.
In China, rapid economic development and the use of eye health education, seriously flawed, making China the largest country in the world's blind people, about 9 million visually disabled. The dry eye, chronic conjunctivitis, glaucoma and retinopathy, the incidence rate significantly increased, the medical profession urgently need a new type of eye medication available to reverse the current status of high incidence of eye disease. As the National Sight Day slogan: "Everyone has the Right to Sight."
High-profile global market
Ophthalmology medicine is a naturally formed an independent system, and clinical drug has certain characteristics, in the formulation, the basic drugs for eye drops and eye ointment gel-based, according to the latest 2009 statistics of hospital medicine, internal Eye Hospital mainly include four kinds of medication dosage forms: eye drops, eye ointment gels, tablets and injections, including eye drops and eye ointment gels occupied for more than 8 into the share.
The unique nature of ophthalmic drugs, making it the market has long been a number of ophthalmic specialty pharmaceutical company occupied, competition, moderate the growth rate is also very limited. However, as other major therapeutic areas, drug market saturation, large pharmaceutical companies are also looking to get into specialty markets, its strong R & D capabilities and efficient marketing to promote market growth makes the rapid increase in ophthalmic drug, Pfizer's Xalatan, and Roche, Novartis co-promotion of Lucentis have entered a "blockbuster" in the ranks.
All along, the ophthalmic drug market is a profitable area, but due to market a smaller scale, very few multi-national pharmaceutical giants will focus on here, therefore, ophthalmic prescription drug market has long been Alcon, Allergan, and trees and other professional ophthalmology company occupied varieties to the main anti-inflammatory anti-inflammatory medication.
However, as a breakthrough in glaucoma drug study, prostaglandins, and Zuo-amine dosage of the rapid rise in intraocular pressure lowering drug market has stimulated the rapid growth - in 2008, Pfizer's latanoprost 1.745 billion global sales U.S. dollars, the total sales of goods listed so far have been more than 10 billion U.S. dollars, while Merck's drug Sato amine compound dorzolamide-timolol, in 2008 sales reached 7.8 billion U.S. dollars.
With the development of modern society, with substantial increases in the incidence of dry eye syndrome, therefore, sales of artificial tears significantly improved, Alcon, as well as the tears ran the Hyalein towering single-product sales exceeded 200 million U.S. dollars. The retinopathy has recently been a very hot area of research, Novartis and Roche jointly marketed for the treatment of retinal neovascular disease, Lucentis (ranibizumab) in 2006, listed 2008 sales reached 17.68 U.S. dollars, exceeding Latanoprost eye become the world's best-selling drug.
In glaucoma, retinopathy and other drugs under the impetus of 2008, the global ophthalmic market for prescription drugs mark the first time exceeded 10 billion U.S. dollars, reaching 10.545 billion U.S. dollars, representing 13.2% growth in 2007, much higher than the overall increase in drugs.
R & D worth the wait
As a potential growth area of medicine, the future development trend of ophthalmic drugs do? In this, the author briefly ophthalmic drug development trend of the future for the peer reference.
The field of glaucoma drug research is now generally agreed that the optic nerve protection will become the future direction of development. Optic nerve protection theory that, through the intervention of drugs or other means of access blocked optic nerve injury and enhanced survival mechanism of retinal ganglion cells, so that those who have not damaged or only partially damaged, or are in a toxic environment within the near death of retinal neurons ganglion cells survived or extend their survival time in order to cure glaucoma and other eye diseases. However, according to the mechanism of the drug generally is still in the early stages of development. Recently, the glaucoma drug R & D hot spots, or find a better Prostaglandins glaucoma medication and research compounds.
Tafluprost is a novel prostaglandin-type drugs by the Japanese Chihisa and Merck jointly develop and its receptor selective higher clinical efficacy was significantly better than latanoprost, the product is expected by the end of this year in the global market; Love Erkang developed brinzolamide eye drops Quwo prostaglandin compound is currently in Phase ? clinical, clinical results show that the dose of compound preparation significantly reduced, and a strong antihypertensive effect.
Anti-inflammatory and anti-infection drug research and development area of the direction of the current mainly two: First, some antibacterial effect stronger, broader antibacterial spectrum of antibiotics and gradually developed ophthalmic preparations, which will improve a large extent on the serious ophthalmic antibiotic resistance problems, such as Alcon's moxifloxacin / dexamethasone compound preparation and the United States InSite's release of azithromycin are listed on the recently approved. Second, anti-inflammatory medication, a number of biological products has shown the exact mitigation keratoconjunctivitis Yandeng eye disease and uveal inflammatory effect and safety of biological products was significantly higher than the existing anti-inflammatory medication. There are already developed by the domestic manufacturers of recombinant human epidermal growth factor (Yi Pui), basic fibroblast growth factor (bFGF) and other biological products market, the market prospect.
Dry eye medication for existing methods of treatment of dry eye syndrome is mainly artificial tear replacement therapy, but most artificial tears contain preservatives and preservative-induced dry eye syndrome is one of the reasons. In addition, artificial tears and the tears, after all, there is still difference, it is difficult to avoid the not irritate the eyes.
Prolacria is a mechanism developed by Inspire's novel dry eye medication, it is by stimulating the eye surface and eyelid lining in the P2Y2 receptor, increasing the key component of natural tears, water, salt, mucin and lipid secretion. Tear film of these major components of the increase in tear volume and composition would improve the use of artificial tears more than simply improve the patient's eye function. In addition, the study found that dry eye syndrome, and genetic and autoimmune bears a closer relationship, the study concluded that, through gene therapy, to improve the dry eye patients have abnormal expression of vitamin A, so that lacrimal gland secretion to normal, and basically remove the dry eye disease. In addition, the dry eye Sjogren's syndrome has also been classified as a category, according to TCM theory, dry eye is dry card areas, dry blood body fluid evil injury, leaving Yin-chun, wear and tear, for the Chinese medicine conditioning also enable the The lacrimal gland function in some patients returned to normal.
The field of angiogenesis drugs, these drugs will be the future of ophthalmology market, important species, early studies have found that by inhibiting angiogenesis around the tumor may block the tumor's nutrient supply, which would act as a "starving to death" the role of the tumor, and this drugs for certain retinal degenerative diseases such as age, sex spot also has excellent results, is currently the best-selling clinical ophthalmology drug Lucentis is a vascular endothelial growth factor (VEGF) antibody, can inhibit angiogenesis, for retinal neovascular diseases, such as wet age-related macular degeneration (wet AMD), proliferative diabetic retinopathy and cystoid macular edema and other diseases have a definite effect.
While in Phase ? clinical VEGF trap-eye is considered to be the next one "blockbuster" level drug, Bayer 2006, up to 375 million U.S. dollars of the transfer price to obtain the drug without U.S. sales license . VEGF trap-eye is a company developed by Regeneron angiogenesis inhibitors by human VEGF receptor 1 and receptor 2 extracellular domain and human immunoglobulin (IgG) together to form a segment of the Fc fusion protein with the affinity of VEGF is much higher than Lucentis, In addition, the role of the drug have anti-PLGF can further enhance angiogenesis inhibition.
It is understood that the current domestic market of such drugs have not yet, but recently in Hong Kong at the World Ophthalmology Congress, West China Hospital of Sichuan Province in China is introduced to Dr. Zhang Ming independently developed neovascularization inhibitor KH902. The drug for high-affinity VEGF receptor, recombinant fusion protein, ? Phase I clinical display, for wet AMD patients, the drug efficacy of precise visual acuity after treatment in patients with an average of 20 letters, is currently in clinical trials to improve eyesight reported the most significant drugs, which also shows that, despite domestic enterprises and multinational giants in research and development there are still a wide gap, but for the development of original drugs, domestic enterprises do not do anything.
Even if the eye in recent years, achieved a series of breakthroughs in drug research, but for the optic atrophy, neovascular glaucoma, macular degeneration such as shrinkage of some difficult diseases, lack of treatment programs, in particular, a large number of basic research needed to provide support for pharmaceutical research. In addition, the face of various refractive errors, especially myopia, there is no a definite advent of effective drugs, so we look forward to a more safe and effective drug treatment of myopia at an early date for clinical, but also believe that this time, and not far away. I am a professional writer from China Manufacturers, which contains a great deal of information about salvage clothing , petite dresses cocktail, welcome to visit!
Related Articles -
salvage clothing, petite dresses cocktail,
|
